First Time Loading...

Catalent Inc

Watchlist Manager
Catalent Inc Logo
Catalent Inc
Price: 37.18 USD -0.72% Market Closed
Updated: Dec 11, 2023

Intrinsic Value

Valuation History
Catalent Inc

Historical Profit
Current Valuation
Price & Value Correlation
Value CAGR
Intrinsic Value History...

Our system is conducting in-depth analyses to map out the stock's valuation journey. Thank you for waiting.

Fundamental Analysis

2024-Q1 Earnings Call
Artifical Intelligence Analysis

Company reasserts full year guidance, bearing net loss
Company reasserts full year guidance, bearing net loss

The quarter saw a 4%-6% decline in net revenue at $982 million due to a $85 million decrease in COVID-19 related revenue, offset by growths of 11% and 5% in Biologics and PCH respectively. Adjusted EBITDA plummeted by 38% to $115 million, and the company recorded an adjusted net loss of $19 million. Despite this, fiscal '24 guidance remains unchanged, expecting net revenue between $4.3 billion to $4.5 billion (3% growth at midpoint), adjusted EBITDA from $680 million to $760 million, and adjusted net income ranging from $113 million to $175 million.


Balance Sheet Decomposition
Catalent Inc

Current Assets 2.7B
Cash & Short-Term Investments 252m
Receivables 1.5B
Other Current Assets 949m
Non-Current Assets 8.1B
PP&E 3.7B
Intangibles 4B
Other Non-Current Assets 386m
Current Liabilities 1.5B
Accounts Payable 394m
Accrued Liabilities 279m
Other Current Liabilities 814m
Non-Current Liabilities 4.6B
Long-Term Debt 4.3B
Other Non-Current Liabilities 379m
Fundamental Scores

CTLT Profitability Score
Profitability Due Diligence

Catalent Inc's profitability score is 48/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive 3-Years Revenue Growth
Positive Operating Income
Positive 3-Year Average ROE

Catalent Inc's profitability score is 48/100. The higher the profitability score, the more profitable the company is.

CTLT Solvency Score
Solvency Due Diligence

Catalent Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Average Altman Z-Score

Catalent Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CTLT Price Targets Summary
Catalent Inc

Wall Street analysts forecast CTLT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CTLT is 49.54 USD with a low forecast of 40.4 USD and a high forecast of 60.9 USD.

Price Target
40.4 USD
9% Upside
Price Target
49.54 USD
33% Upside
Price Target
60.9 USD
64% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape


CTLT Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

CTLT Return Decomposition
Main factors of price return

What is price return decomposition?

CTLT Price
Catalent Inc

1M 1M
6M 6M
1Y 1Y
3Y 3Y
5Y 5Y
10Y 10Y
Annual Price Range
52w Low
52w High
Price Metrics
Average Annual Return 42.9%
Standard Deviation of Annual Returns 48.64%
Max Drawdown -78%
Shares Statistics
Market Capitalization 6.7B USD
Shares Outstanding 180 270 000
Percentage of Shares Shorted 6.64%


Last Video News
Catalent Inc

Other Videos

Last Important Events
Catalent Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.


Sentiment Analysis
Catalent Inc

Last 7 Days
Last 30 Days
Last 90 Days

Company Profile

Catalent Inc Logo
Catalent Inc


United States of America



Market Cap

6.7B USD

Dividend Yield



Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. The company is headquartered in Somerset, New Jersey and currently employs 17,300 full-time employees. The company went IPO on 2014-07-31. Its segments include Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment is engaged in providing formulation, development, and manufacturing services for soft capsules, as well as largescale manufacturing of oral solid dose forms. The Biologics segment provides biologic cell-line, cell therapy and viral vector gene therapy development and manufacturing services. The Oral and Specialty Delivery segment provides formulation development and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is engaged in manufacturing, packaging, distribution and inventory management for drugs and biologics in clinical trials.


14 Schoolhouse Rd




17 300


Exec. Chair of the Board
Mr. John R. Chiminski
CEO & Director
Mr. Alessandro Maselli
Sr. VP & CFO
Mr. Thomas P. Castellano
Exec. VP, Corp. Sec. & Chief Admin. Officer
Mr. Steven L. Fasman Esq.
Group Pres of Pharma & Consumer Health Segment
Dr. Aristippos Gennadios Ph.D.
Pres & Division Head for Clinical Devel. and Supply
Mr. Ricky Hopson
Show More
VP & Chief Accounting Office
Ms. Karen Murphy Santiago
VP & Chief Scientific Officer
Mr. Julien Meissonnier
Sr. VP & Chief Information Officer
Mr. Charles Lickfold
VP of Investor Relations
Mr. Paul Surdez
Show Less

See Also

Discover More
What is the Intrinsic Value of one CTLT stock?

The intrinsic value of one CTLT stock under the Base Case scenario is 57.41 USD.

Is CTLT stock undervalued or overvalued?

Compared to the current market price of 37.18 USD, Catalent Inc is Undervalued by 35%.